FDA will ask Sarepta to stop selling Duchenne treatment, following patient deaths

The FDA will ask Sarepta to stop shipping its Duchenne muscular dystrophy treatment Elevidys, an HHS official said, in what could be a final blow to the company's hopes for the product following two patients' ...